(Q65392988)

English

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects (English)

0 references

sponsor

Hoffmann-La Roche

0 references

country

United States of America

0 references

start time

31 March 2016

0 references

end time

28 September 2016

0 references

number of participants

18

0 references

clinical trial phase

phase I clinical trial

0 references

minimum age

18 year

0 references

maximum age

45 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02711423

0 references

(Q65392988)

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)